Log In
Print
BCIQ
Print
Print this Print this
 

letermovir (AIC246, MK-8228)

  Manage Alerts
Collapse Summary General Information
Company AiCuris GmbH & Co. KG
DescriptionQuinazoline-based inhibitor of the cytomegalovirus (CMV) terminase protein
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent clinically significant cytomegalovirus (CMV) infection; Prevent cytomegalovirus (CMV) infection in at-risk populations; Prevent cytomegalovirus (CMV) infection in human blood precursor cell (HBPC) transplant recipients; Prevent cytomegalovirus infection in solid organ or bone marrow transplant recipients; Treat cytomegalovirus (CMV) infection
Regulatory Designation

U.S. - Fast Track (Treat cytomegalovirus (CMV) infection);
U.S. - Orphan Drug (Treat cytomegalovirus (CMV) infection);
U.S. - Orphan Drug (Prevent cytomegalovirus (CMV) infection in at-risk populations);
EU - Orphan Drug (Prevent cytomegalovirus (CMV) infection in at-risk populations);
EU - Orphan Drug (Treat cytomegalovirus (CMV) infection)

Partner

Merck & Co. Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today